See every side of every news story
Published loading...Updated

BioLife Solutions Reports Second Quarter 2025 Financial Results

UNITED STATES, AUG 8 – Mount Logan Capital highlights strong Q2 revenue growth and profitability, including Astrana's acquisition of Prospect Health and Dynavax's 31% increase in HEPLISAV-B vaccine net revenue.

  • BioLife Solutions reported its financial performance for the second quarter and first half of 2025, highlighting strong revenue growth and an upward revision to its full-year 2025 guidance.
  • BioLife increased its revenue outlook for 2025, now anticipating total revenues between $100 million and $103 million, driven by strong sales and growing demand for its cell processing products.
  • Q2 2025 revenue reached $25.4 million, reflecting a 29% rise compared to 2024, driven by a 28% growth in Cell Processing revenue to $23.0 million, while adjusted EBITDA stood at $6.1 million.
  • BioLife reported a GAAP gross margin of 62% in Q2 2025 and recorded an operating loss of $16.6 million, primarily driven by a $15.5 million intangible asset impairment related to in-process research and development.
  • The results and financial strength support BioLife’s outlook for sustained growth amid expansion in the cell and gene therapy market and ongoing product investments.
Insights by Ground AI
Does this summary seem wrong?

47 Articles

Journal Gazette & Times-CourierJournal Gazette & Times-Courier
+20 Reposted by 20 other sources
Center

AgriBank Reports Second Quarter 2025 Financial Results

Continued strong financial performance reflects AgriBank business model, Association success

Seeking AlphaSeeking Alpha
+8 Reposted by 8 other sources
Lean Right

Power Solutions International Announces Record Second Quarter 2025 Financial Results

·United States
Read Full Article
Aspen Daily NewsAspen Daily News
+10 Reposted by 10 other sources
Center

Dynavax Reports Second Quarter 2025 Financial Results

Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 64% of the sources are Center
64% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Inside Ottawa Valley broke the news in Ottawa, Canada on Thursday, August 7, 2025.
Sources are mostly out of (0)

Similar News Topics